IL312393A - A method or factor with an HDAC regulator, for the treatment of diabetes and complications - Google Patents

A method or factor with an HDAC regulator, for the treatment of diabetes and complications

Info

Publication number
IL312393A
IL312393A IL312393A IL31239324A IL312393A IL 312393 A IL312393 A IL 312393A IL 312393 A IL312393 A IL 312393A IL 31239324 A IL31239324 A IL 31239324A IL 312393 A IL312393 A IL 312393A
Authority
IL
Israel
Prior art keywords
diabetes mellitus
blood glucose
treatment
insulin
hdac
Prior art date
Application number
IL312393A
Other languages
English (en)
Hebrew (he)
Inventor
Miwako Katagi
Hideto Kojima
Original Assignee
Biozipcode Inc
Miwako Katagi
Hideto Kojima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biozipcode Inc, Miwako Katagi, Hideto Kojima filed Critical Biozipcode Inc
Publication of IL312393A publication Critical patent/IL312393A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL312393A 2021-10-29 2022-10-27 A method or factor with an HDAC regulator, for the treatment of diabetes and complications IL312393A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021177845 2021-10-29
PCT/JP2022/040140 WO2023074794A1 (ja) 2021-10-29 2022-10-27 Ｈｄａｃ調節剤による糖尿病ならびに合併症の治療方法または治療剤

Publications (1)

Publication Number Publication Date
IL312393A true IL312393A (en) 2024-06-01

Family

ID=86159956

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312393A IL312393A (en) 2021-10-29 2022-10-27 A method or factor with an HDAC regulator, for the treatment of diabetes and complications

Country Status (7)

Country Link
EP (1) EP4424327A4 (https=)
JP (1) JPWO2023074794A1 (https=)
KR (1) KR20240093575A (https=)
CN (1) CN118475370A (https=)
AU (1) AU2022376087A1 (https=)
IL (1) IL312393A (https=)
WO (1) WO2023074794A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114828890A (zh) * 2019-10-18 2022-07-29 比奥兹普科德公司 使用了干细胞迁移剂的糖尿病治疗
JP2021177845A (ja) 2020-05-12 2021-11-18 株式会社サンセイアールアンドディ 遊技機
KR20230152099A (ko) * 2021-02-26 2023-11-02 가부시키가이샤 바이오지프코드 당뇨병 및 합병증의 신규 치료, 진단 및 검출을 위한 방법 및 제제

Also Published As

Publication number Publication date
JPWO2023074794A1 (https=) 2023-05-04
EP4424327A4 (en) 2025-12-31
WO2023074794A1 (ja) 2023-05-04
EP4424327A1 (en) 2024-09-04
CN118475370A (zh) 2024-08-09
AU2022376087A1 (en) 2024-06-13
KR20240093575A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
Mori et al. Critical roles for the TSC-mTOR pathway in β-cell function
JP6301995B2 (ja) 分泌されたａＰ２およびこれを阻害する方法
Li et al. NLRP3 inflammasome-modulated angiogenic function of EPC via PI3K/Akt/mTOR pathway in diabetic myocardial infarction
Arivazhagan et al. Glycation and a spark of ALEs (advanced lipoxidation end products)–igniting RAGE/Diaphanous-1 and cardiometabolic disease
JP2023139101A (ja) 幹細胞遊走剤を使用した糖尿病治療
US20240139129A1 (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
EP1900374B1 (en) Angiogenetic agent containing adrenomedulin as the active ingredient
IL312393A (en) A method or factor with an HDAC regulator, for the treatment of diabetes and complications
HK40105070A (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
US20230025003A1 (en) Diabetes therapy targeting abnormal stem cells
Zhang et al. Cardiovascular and brain effects of liraglutide in transthyretin amyloidosis (ATTR) mice models
HK40074315A (en) Therapy for diabetes using stem cell migration agent
HK40073790A (en) Diabetes therapy targeting abnormal stem cells
HK40073547A (en) Therapy for diabetes using stem cell migration agent
EP1705256A1 (en) Methods for the treatment of insulin resistance and disease states characterized by insulin resistance
HK40073293A (en) Diabetes therapy targeting abnormal stem cells
Bauer The Impact of Mig6 on Pancreatic Endocrine Cell Fate: Alpha and Beta Cell Mass in Health and Disease
Malinauskas et al. Effects of GLP-1 and GIP on cholinergic-induced contractility in isolated jejunal muscle from obese patients with and without type 2 diabetes mellitus
Seelam GLP1R IS AT CELL NEGATIVE COSTIMULATORY MOLECULE
Chen et al. 1Department of Critical Care Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, No. 136, Jingzhou Street, Xiangcheng District, Xiangyang 441021, Hubei, China. 2Department of Emergency Medicine, Xiangyang Central Hospital
NZ786536A (en) Methods of treating diseases associated with ILC2 cells